Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.

Sarkar S, Chauhan SKS, Daly J, Natoni A, Fairfield H, Henderson R, Nolan E, Swan D, Hu J, Reagan MR, O'Dwyer M.

Cancer Immunol Immunother. 2020 Mar;69(3):421-434. doi: 10.1007/s00262-019-02477-8. Epub 2020 Jan 9.

PMID:
31919623
2.

Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14).

Swan D, Delaney C, Natoni A, O'Dwyer M, Krawczyk J.

Haematologica. 2019 Nov 21. pii: haematol.2019.228338. doi: 10.3324/haematol.2019.228338. [Epub ahead of print] No abstract available.

3.

Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment.

Natoni A, Bohara R, Pandit A, O'Dwyer M.

Front Bioeng Biotechnol. 2019 Oct 4;7:252. doi: 10.3389/fbioe.2019.00252. eCollection 2019. Review.

4.

CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.

O'Dwyer M, Henderson R, Naicker SD, Cahill MR, Murphy P, Mykytiv V, Quinn J, McEllistrim C, Krawczyk J, Walsh J, Lenihan E, Kenny T, Hernando A, Hirakata G, Parker I, Kinsella E, Gannon G, Natoni A, Lynch K, Ryan AE.

Blood Adv. 2019 Jun 25;3(12):1815-1825. doi: 10.1182/bloodadvances.2019000010.

5.

Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model.

Natoni A, Farrell ML, Harris S, Falank C, Kirkham-McCarthy L, Macauley MS, Reagan MR, O'Dwyer M.

Haematologica. 2020 Jan 31;105(2):457-467. doi: 10.3324/haematol.2018.212266. Print 2020.

6.

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.

Natoni A, Smith TAG, Keane N, McEllistrim C, Connolly C, Jha A, Andrulis M, Ellert E, Raab MS, Glavey SV, Kirkham-McCarthy L, Kumar SK, Locatelli-Hoops SC, Oliva I, Fogler WE, Magnani JL, O'Dwyer ME.

Leukemia. 2017 Dec;31(12):2642-2651. doi: 10.1038/leu.2017.123. Epub 2017 Apr 25.

7.

Targeting Selectins and Their Ligands in Cancer.

Natoni A, Macauley MS, O'Dwyer ME.

Front Oncol. 2016 Apr 18;6:93. doi: 10.3389/fonc.2016.00093. eCollection 2016. Review.

8.

Targeting the Pim kinases in multiple myeloma.

Keane NA, Reidy M, Natoni A, Raab MS, O'Dwyer M.

Blood Cancer J. 2015 Jul 17;5:e325. doi: 10.1038/bcj.2015.46. Review.

9.

The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.

Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, Zhang Y, Zhang W, Zhang Y, Morgan G, Joshi L, Roccaro AM, Ghobrial IM, O'Dwyer ME.

Blood. 2014 Sep 11;124(11):1765-76. doi: 10.1182/blood-2014-03-560862. Epub 2014 Jul 24.

10.

A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response.

FitzGerald J, Murillo LS, O'Brien G, O'Connell E, O'Connor A, Wu K, Wang GN, Rainey MD, Natoni A, Healy S, O'Dwyer M, Santocanale C.

PLoS One. 2014 Jun 5;9(6):e98891. doi: 10.1371/journal.pone.0098891. eCollection 2014.

11.

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models.

Natoni A, Coyne MR, Jacobsen A, Rainey MD, O'Brien G, Healy S, Montagnoli A, Moll J, O'Dwyer M, Santocanale C.

Cancers (Basel). 2013 Jul 24;5(3):901-18. doi: 10.3390/cancers5030901.

12.

A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization.

Natoni A, O'Dwyer M, Santocanale C.

Methods Mol Biol. 2013;986:217-26. doi: 10.1007/978-1-62703-311-4_14.

PMID:
23436415
13.

NOXA contributes to the sensitivity of PERK-deficient cells to ER stress.

Gupta S, Giricz Z, Natoni A, Donnelly N, Deegan S, Szegezdi E, Samali A.

FEBS Lett. 2012 Nov 16;586(22):4023-30. doi: 10.1016/j.febslet.2012.10.002. Epub 2012 Oct 12.

14.

Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.

Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O'Dwyer M, Santocanale C.

Mol Cancer Ther. 2011 Sep;10(9):1624-34. doi: 10.1158/1535-7163.MCT-10-1119. Epub 2011 Jul 18.

15.

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.

Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M, Sjollema K, Stricher F, Cool RH, Samali A, Serrano L, Quax WJ.

Cell Death Dis. 2010 Oct 21;1:e83. doi: 10.1038/cddis.2010.61.

16.

Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation.

Napolitano C, Natoni A, Santocanale C, Evensen L, Lorens JB, Murphy PV.

Bioorg Med Chem Lett. 2011 Feb 15;21(4):1167-70. doi: 10.1016/j.bmcl.2010.12.100. Epub 2010 Dec 24.

PMID:
21273066
17.

Targeting AML through DR4 with a novel variant of rhTRAIL.

Szegezdi E, Reis CR, van der Sloot AM, Natoni A, O'Reilly A, Reeve J, Cool RH, O'Dwyer M, Knapper S, Serrano L, Quax WJ, Samali A.

J Cell Mol Med. 2011 Oct;15(10):2216-31. doi: 10.1111/j.1582-4934.2010.01211.x.

18.

Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.

Mahalingam D, Natoni A, Keane M, Samali A, Szegezdi E.

Br J Cancer. 2010 Feb 16;102(4):754-64. doi: 10.1038/sj.bjc.6605545. Epub 2010 Jan 19.

19.

Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.

Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH, Samali A, Serrano L, Quax WJ.

Biochemistry. 2009 Mar 17;48(10):2180-91. doi: 10.1021/bi801927x.

PMID:
19236007
20.

TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.

Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, Stover DR, Dyer MJ, Cohen GM.

Br J Haematol. 2007 Nov;139(4):568-77. Epub 2007 Oct 8.

PMID:
17922877
21.

Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells.

Belfiore MC, Natoni A, Barzellotti R, Merendino N, Pessina G, Ghibelli L, Gualandi G.

Cancer Lett. 2007 Sep 8;254(2):236-43. Epub 2007 Apr 27.

PMID:
17467166
22.

The mitochondrial pathway of apoptosis is triggered during feline calicivirus infection.

Natoni A, Kass GE, Carter MJ, Roberts LO.

J Gen Virol. 2006 Feb;87(Pt 2):357-61.

PMID:
16432022
23.

Calicivirus translation initiation requires an interaction between VPg and eIF 4 E.

Goodfellow I, Chaudhry Y, Gioldasi I, Gerondopoulos A, Natoni A, Labrie L, Laliberté JF, Roberts L.

EMBO Rep. 2005 Oct;6(10):968-72.

Supplemental Content

Loading ...
Support Center